Advertisement
Advertisement
U.S. Markets open in 4 hrs 50 mins
Advertisement
Advertisement
Advertisement
Advertisement

OptiNose, Inc. (OPTN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.8300-0.0900 (-3.08%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.9200
Open2.9300
Bid0.0000 x 1000
Ask0.0000 x 1300
Day's Range2.8100 - 2.9350
52 Week Range2.3200 - 5.1100
Volume305,870
Avg. Volume269,021
Market Cap150.309M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-1.9380
Earnings DateMay 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
  • GlobeNewswire

    Optinose to Present at the Cantor Virtual Global Healthcare Conference

    YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 8:40 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of

  • GlobeNewswire

    Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incent

  • Zacks

    OptiNose (OPTN) Reports Q2 Loss, Tops Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of -2.33% and 5.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement